Furthermore, in the phase II clinical trial, a combination of IFNα and chemotherapy (Oxaliplatin/Adriamycin/5-Fluorouracil) showed manageable toxicity and improved survival of patients with advanced hepatocellular carcinoma [25]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.